Organization | Hospital Federal de Bonsucesso

Hospital Federal de Bonsucesso Report issue

Academic/Hospital Phase 1 Phase 4

Founded: Rio de Janeiro Brazil (1948)

Organization Overview

First Clinical Trial

2009

NCT01841775

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2018

Timeline

NOW

Now

Alternative names

Hospital Federal de Bonsucesso | Hospital Federal de Bonsucesso (Bonsucesso Federal Hospital) | Hospital federal of Bonsucesso

Active Ingredients

Drugs in Phase 4 Trials (10)

aprepitant (Emend) (1 trial)

cyclosporine (sandimmune) (1 trial)

everolimus (zortress) (1 trial)

interferon alpha-2b (Intron-A) (1 trial)

magnesium sulfate (Tis-U-Sol) (3 trials)

ondansetron (zofran) (1 trial)

palonosetron (aloxi) (2 trials)

ribavirin (virazole) (1 trial)

sodium chloride (3 trials)

tacrolimus (prograf) (1 trial)

Drugs in Phase 1 Trials (1)

autologous mesenchymal stem cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis C (Phase 4)

Hepatitis C, Chronic (Phase 4)

Lipodystrophy (Phase 1)

Nausea (Phase 4)

Postoperative Nausea and Vomiting (Phase 4)

Vomiting (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 8
# of Trial APIs: 11